Shock Analytics is an early stage biomedical device firm focused on the development of smarter technologies for treating acute and chronic illnesses. Our initial focus is on a noninvasive device to estimate Systemic Vascular Resistance (SVR).

Development of this fifth vital sign can transform early diagnosis of shock and the treatment of heart failure. These are the two most expensive illnesses in modern medicine, and they claim millions of lives globally per year. Easier diagnosis and ability to track hemodynamics in a simple and actionable way can improve care and reduce costs of these disease states.

Shock Analytics was founded by a cardiologist and two biomedical engineers and was spun out from the University of Pennsylvania through the UPstart Incubator.